Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Colorectal Neoplasms 9Carcinoma, Non-Small-Cell Lung 2Thyroid Neoplasms 1Ras-mutated Metastatic Colorectal Cancer 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Lung Neoplasms 1Histiocytosis 1Gastrointestinal Neoplasms 1Colonic Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Neuroendocrine 1Carcinoma, Basal Cell 1CRC 1Brain Neoplasms 1Advanced Gastric or EGJ Cancer 1

Interventions

Nivolumab 3Cisplatin 3atezolizumab 2Irinotecan 2Ipilimumab 2Etoposide 2Carboplatin 2tivozanib 1repotrectinib 1niraparib 1gallium Ga 68 dotatate 1dostarlimab 1cabozantinib 1budigalimab 1belinostat 1Topotecan 1Temozolomide 1Specimen Handling 1Radiosurgery 1Radionuclide Imaging 1Positron-Emission Tomography 1Positron Emission Tomography Computed Tomography 1Magnetic Resonance Spectroscopy 1Leucovorin 1Immunoglobulin G 1IFL protocol 1Fluorouracil 1Disulfides 1DLL3 protein, human 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Neuroendocrine × IFL protocol × 90 days × Clear all
NCT07595913 2026-05-19

A Study of ZG006 for Injection Versus Investigator-Selected Chemotherapy in Participants With Advanced Neuroendocrine Carcinoma

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Phase 3 Not yet recruiting
240 enrolled
Endocrine

Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon âš¡